Context Therapeutics shares are trading higher after HC Wainwright upgraded the stock from Neutral to Buy and announced a $5 price target.
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright has upgraded Context Therapeutics from Neutral to Buy and set a price target of $5. This has led to an increase in the trading of Context Therapeutics' shares.
November 01, 2023 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Context Therapeutics' stock has been upgraded by HC Wainwright from Neutral to Buy, with a price target of $5. This has resulted in increased trading of the company's shares.
The upgrade from HC Wainwright is a positive signal for Context Therapeutics. It indicates that the analyst firm sees potential for the stock's price to increase, hence the Buy rating and the $5 price target. This news has already led to increased trading of the company's shares, indicating that investors are reacting positively to the upgrade.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100